In last trading session, Hepion Pharmaceuticals Inc (NASDAQ:HEPA) saw 9.84 million shares changing hands with its beta currently measuring 1.65. Company’s recent per share price level of $0.19 trading at $0.01 or 5.42% at ring of the bell on the day assigns it a market valuation of $1.98M. That closing price of HEPA’s stock is at a discount of -1736.84% from its 52-week high price of $3.49 and is indicating a premium of 36.84% from its 52-week low price of $0.12. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 99.35 million shares which gives us an average trading volume of 16.35 million if we extend that period to 3-months.
For Hepion Pharmaceuticals Inc (HEPA), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 3.00. Splitting up the data highlights that, out of 1 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 1 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of 0 in the current quarter.
Hepion Pharmaceuticals Inc (NASDAQ:HEPA) trade information
Upright in the green during last session for gaining 5.42%, in the last five days HEPA remained trading in the red while hitting it’s week-highest on Tuesday, 01/28/25 when the stock touched $0.19 price level, adding 32.14% to its value on the day. Hepion Pharmaceuticals Inc’s shares saw a change of -60.31% in year-to-date performance and have moved -6.70% in past 5-day. Hepion Pharmaceuticals Inc (NASDAQ:HEPA) showed a performance of -59.44% in past 30-days. Number of shares sold short was 65726.0 shares which calculate 0.92 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 70 to the stock, which implies a rise of 99.73% to its current value. Analysts have been projecting 70 as a low price target for the stock while placing it at a high target of 70. It follows that stock’s current price would drop -36742.11% in reaching the projected high whereas dropping to the targeted low would mean a loss of -36742.11% for stock’s current value.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 63.67% during past 5 years.
Hepion Pharmaceuticals Inc (NASDAQ:HEPA)’s Major holders
Insiders are in possession of 0.08% of company’s total shares while institution are holding 7.85 percent of that, with stock having share float percentage of 7.85%. Investors also watch the number of corporate investors in a company very closely, which is 7.85% institutions for Hepion Pharmaceuticals Inc that are currently holding shares of the company.
On the other hand, Vanguard Extended Market Index Fund and Vanguard Total Stock Market Index Fund are the top two Mutual Funds which own company’s shares. As of Sep 30, 2024 , the former fund manager was holding 48.91 shares of worth $9126.0 or 0.70% of the total outstanding shares. The later fund manager was in possession of 40.67 shares on Sep 30, 2024 , making its stake of worth around $7589.0 in the company or a holder of 0.58% of company’s stock.
